The latest first-line treatment options for ovarian cancer: focus on maintenance therapy

by A. A. Rumyantsev
Published 2020-12-01

Modern aspects of antiangiogenic therapy in ovarian cancer

by A. A. Rumyantsev, I. A. Pokataev, S. A. Tyulyandin
Published 2018-11-01

Optimizing the primary treatment of patients with advanced ovarian cancer

by S. O. Nikogosyan, V. V. Kuznetsov, A. Z. Zagashtokov, A. A. Rumyantsev
Published 2016-11-01

THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

by A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
Published 2015-09-01

THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY

by A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
Published 2015-09-01

Thyroid gland affection during Hodgkin’s disease

by A. A. Rumyantsev, O. I. Kolesnikova, N. I. Voloskova, A. A. Bakanov
Published 2004-09-01

Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy

by N A Rumyantsev, V G Kukes, R E Kazakov, A A Rumyantsev, D A Sychev
Published 2017-01-01

Monitoring process of developing system for providing temperature, air supply and filtration of transported control modules

by A. A. Girchenko, A. A. Rumyantsev, A. A. Kazantsev, D. I. Bukhanets, A. V. Timoshenko, A. A. Murashev
Published 2020-10-01

Highly Crystalline WO3 Nanoparticles Are Nontoxic to Stem Cells and Cancer Cells

by B. Han, A. L. Popov, T. O. Shekunova, D. A. Kozlov, O. S. Ivanova, A. A. Rumyantsev, A. B. Shcherbakov, N. R. Popova, A. E. Baranchikov, V. K. Ivanov
Published 2019-01-01

REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCE...

by N. S. Besova, T. A. Titova, V. A. Gorbunova, O. O. Gordeeva, A. A. Tryakin, A. V. Snegovoy, R. Yu. Nasyrova, A. A. Rumyantsev, E. A. Voroshilova, E. V. Artamonova
Published 2017-11-01

Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or card...

by N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, A. A. Fedenko
Published 2018-07-01